vs
Akebia Therapeutics, Inc.（AKBA）与RBB Bancorp（RBB）财务数据对比。点击上方公司名可切换其他公司
Akebia Therapeutics, Inc.的季度营收约是RBB Bancorp的1.8倍（$57.6M vs $32.3M），Akebia Therapeutics, Inc.同比增速更快（23.9% vs 12.6%），RBB Bancorp自由现金流更多（$42.6M vs $31.1M），过去两年Akebia Therapeutics, Inc.的营收复合增速更高（32.9% vs 7.0%）
Akebia Therapeutics是一家专注于肾病领域的生物制药企业，核心业务覆盖药物研发、临床试验及商业化推广全流程，主要开发针对慢性肾病相关贫血等适应症的创新疗法，面向全球市场，致力于满足肾病治疗领域未被满足的临床需求。
RBB银行控股公司是总部位于美国的金融控股集团，旗下核心主体为皇家商业银行，主要服务亚裔社群、中小微企业、不动产投资者及零售客户，提供商业信贷、储蓄存款、财富管理等多元金融服务，业务覆盖美国沿海核心都会区。
AKBA vs RBB — 直观对比
营收规模更大
AKBA
是对方的1.8倍
$32.3M
营收增速更快
AKBA
高出11.4%
12.6%
自由现金流更多
RBB
多$11.5M
$31.1M
两年增速更快
AKBA
近两年复合增速
7.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.6M | $32.3M |
| 净利润 | — | $10.2M |
| 毛利率 | 78.2% | — |
| 营业利润率 | -14.8% | 39.5% |
| 净利率 | — | 31.5% |
| 营收同比 | 23.9% | 12.6% |
| 净利润同比 | — | 132.1% |
| 每股收益（稀释后） | $-0.05 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AKBARBB
| Q4 25 | $57.6M | $32.3M | ||
| Q3 25 | $58.8M | $32.6M | ||
| Q2 25 | $62.5M | $35.8M | ||
| Q1 25 | $57.3M | $28.5M | ||
| Q4 24 | $46.5M | $28.7M | ||
| Q3 24 | $37.4M | $30.3M | ||
| Q2 24 | $43.6M | $27.5M | ||
| Q1 24 | $32.6M | $28.2M |
净利润AKBARBB
| Q4 25 | — | $10.2M | ||
| Q3 25 | $540.0K | $10.1M | ||
| Q2 25 | $247.0K | $9.3M | ||
| Q1 25 | $6.1M | $2.3M | ||
| Q4 24 | — | $4.4M | ||
| Q3 24 | $-20.0M | $7.0M | ||
| Q2 24 | $-8.6M | $7.2M | ||
| Q1 24 | $-18.0M | $8.0M |
毛利率AKBARBB
| Q4 25 | 78.2% | — | ||
| Q3 25 | 84.0% | — | ||
| Q2 25 | 84.1% | — | ||
| Q1 25 | 86.7% | — | ||
| Q4 24 | 56.2% | — | ||
| Q3 24 | 62.2% | — | ||
| Q2 24 | 60.9% | — | ||
| Q1 24 | 64.4% | — |
营业利润率AKBARBB
| Q4 25 | -14.8% | 39.5% | ||
| Q3 25 | 7.6% | 40.7% | ||
| Q2 25 | 22.6% | 36.1% | ||
| Q1 25 | 23.6% | 11.2% | ||
| Q4 24 | -30.8% | 17.6% | ||
| Q3 24 | -33.4% | 31.6% | ||
| Q2 24 | -20.0% | 35.6% | ||
| Q1 24 | -45.8% | 39.9% |
净利率AKBARBB
| Q4 25 | — | 31.5% | ||
| Q3 25 | 0.9% | 31.2% | ||
| Q2 25 | 0.4% | 26.1% | ||
| Q1 25 | 10.7% | 8.0% | ||
| Q4 24 | — | 15.3% | ||
| Q3 24 | -53.5% | 23.1% | ||
| Q2 24 | -19.7% | 26.4% | ||
| Q1 24 | -55.2% | 28.4% |
每股收益（稀释后）AKBARBB
| Q4 25 | $-0.05 | $0.59 | ||
| Q3 25 | $0.00 | $0.59 | ||
| Q2 25 | $0.00 | $0.52 | ||
| Q1 25 | $0.03 | $0.13 | ||
| Q4 24 | $-0.10 | $0.26 | ||
| Q3 24 | $-0.10 | $0.39 | ||
| Q2 24 | $-0.04 | $0.39 | ||
| Q1 24 | $-0.09 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $184.8M | $212.3M |
| 总债务越低越好 | $48.3M | $119.9M |
| 股东权益账面价值 | $32.6M | $523.4M |
| 总资产 | $376.6M | $4.2B |
| 负债/权益比越低杠杆越低 | 1.48× | 0.23× |
8季度趋势，按日历期对齐
现金及短期投资AKBARBB
| Q4 25 | $184.8M | $212.3M | ||
| Q3 25 | $166.4M | $234.9M | ||
| Q2 25 | $137.3M | $191.9M | ||
| Q1 25 | $113.4M | $238.8M | ||
| Q4 24 | $51.9M | $257.7M | ||
| Q3 24 | $34.0M | $349.4M | ||
| Q2 24 | $39.5M | $252.8M | ||
| Q1 24 | $42.0M | — |
总债务AKBARBB
| Q4 25 | $48.3M | $119.9M | ||
| Q3 25 | $47.6M | $119.8M | ||
| Q2 25 | $47.1M | $119.7M | ||
| Q1 25 | $46.5M | $119.6M | ||
| Q4 24 | $38.7M | $119.5M | ||
| Q3 24 | $38.4M | $119.4M | ||
| Q2 24 | $38.0M | $119.3M | ||
| Q1 24 | $30.1M | $119.2M |
股东权益AKBARBB
| Q4 25 | $32.6M | $523.4M | ||
| Q3 25 | $41.6M | $514.3M | ||
| Q2 25 | $29.2M | $517.7M | ||
| Q1 25 | $24.6M | $510.3M | ||
| Q4 24 | $-49.2M | $507.9M | ||
| Q3 24 | $-50.4M | $509.7M | ||
| Q2 24 | $-33.8M | $511.3M | ||
| Q1 24 | $-27.3M | $514.0M |
总资产AKBARBB
| Q4 25 | $376.6M | $4.2B | ||
| Q3 25 | $364.2M | $4.2B | ||
| Q2 25 | $345.6M | $4.1B | ||
| Q1 25 | $310.2M | $4.0B | ||
| Q4 24 | $220.7M | $4.0B | ||
| Q3 24 | $207.1M | $4.0B | ||
| Q2 24 | $220.2M | $3.9B | ||
| Q1 24 | $225.5M | $3.9B |
负债/权益比AKBARBB
| Q4 25 | 1.48× | 0.23× | ||
| Q3 25 | 1.15× | 0.23× | ||
| Q2 25 | 1.61× | 0.23× | ||
| Q1 25 | 1.89× | 0.23× | ||
| Q4 24 | — | 0.24× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $31.1M | $43.4M |
| 自由现金流经营现金流 - 资本支出 | $31.1M | $42.6M |
| 自由现金流率自由现金流/营收 | 53.9% | 131.8% |
| 资本支出强度资本支出/营收 | 0.1% | 2.5% |
| 现金转化率经营现金流/净利润 | — | 4.26× |
| 过去12个月自由现金流最近4个季度 | $67.7M | $73.5M |
8季度趋势，按日历期对齐
经营现金流AKBARBB
| Q4 25 | $31.1M | $43.4M | ||
| Q3 25 | $28.1M | $2.1M | ||
| Q2 25 | $22.3M | $21.7M | ||
| Q1 25 | $-13.6M | $7.8M | ||
| Q4 24 | $-4.5M | $58.5M | ||
| Q3 24 | $-6.7M | $24.5M | ||
| Q2 24 | $-10.1M | $11.7M | ||
| Q1 24 | $-19.4M | $4.8M |
自由现金流AKBARBB
| Q4 25 | $31.1M | $42.6M | ||
| Q3 25 | $28.0M | $1.8M | ||
| Q2 25 | $22.2M | $21.6M | ||
| Q1 25 | $-13.6M | $7.6M | ||
| Q4 24 | $-4.5M | $57.7M | ||
| Q3 24 | $-6.7M | $24.2M | ||
| Q2 24 | $-10.1M | $11.5M | ||
| Q1 24 | — | $4.7M |
自由现金流率AKBARBB
| Q4 25 | 53.9% | 131.8% | ||
| Q3 25 | 47.7% | 5.4% | ||
| Q2 25 | 35.6% | 60.2% | ||
| Q1 25 | -23.7% | 26.7% | ||
| Q4 24 | -9.6% | 201.0% | ||
| Q3 24 | -17.9% | 80.0% | ||
| Q2 24 | -23.1% | 42.0% | ||
| Q1 24 | — | 16.6% |
资本支出强度AKBARBB
| Q4 25 | 0.1% | 2.5% | ||
| Q3 25 | 0.1% | 1.1% | ||
| Q2 25 | 0.2% | 0.3% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.0% | 2.7% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.1% | 0.5% | ||
| Q1 24 | 0.0% | 0.5% |
现金转化率AKBARBB
| Q4 25 | — | 4.26× | ||
| Q3 25 | 52.05× | 0.21× | ||
| Q2 25 | 90.47× | 2.32× | ||
| Q1 25 | -2.22× | 3.39× | ||
| Q4 24 | — | 13.34× | ||
| Q3 24 | — | 3.50× | ||
| Q2 24 | — | 1.61× | ||
| Q1 24 | — | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AKBA
| Auryxia | $48.1M | 84% |
| Vafseo | $6.2M | 11% |
| License Collaboration And Other Revenue | $3.3M | 6% |
RBB
暂无分部数据
